Anti‐tumor necrosis factor‐alpha therapy improves endothelial function and arterial stiffness in patients with moderate to severe psoriasis: A 6‐month prospective study

• DOI: 10.1111/1346-8138.13398
• Publication Date: 2016-04-10T17:43:19Z
• Authors: Trinitario Pina; Alfonso Corrales; Raquel Lopez‐Mejias; Susana Armesto; Marcos A. Gonzale...; Ines Gómez‐Acebo; Begoña Ubilla; Sara Remuzgo‐Mart...; M. Carmen Gonzale...; Ricardo Blanco; Jose L. Hernández; Javier Llorca; Miguel A. Gonzale...
• Keywords: Brachial artery; Endothelial Dysfunction

Abstract The aim of the present study was to determine if use anti‐tumor necrosis factor ( TNF )‐α monoclonal antibody adalimumab could improve endothelial function and arterial stiffness in patients with moderate severe psoriasis. This a prospective on series consecutive psoriasis who completed 6 months therapy adalimumab. Patients history cardiovascular events, diabetes mellitus, kidney disease, hypertension or body mass index 35 kg/m 2 more were excluded. Assessment by brachial artery reactivity measuring flow‐mediated dependent vasodilatation FMD %), carotid pulse wave velocity PWV ) performed at onset treatment (time 0) month 6. Twenty‐nine studied. Anti‐ ‐α yielded significant improvement function. mean ± standard deviation SD % values increased from 6.19 2.44% 7.46 2.43% after this biologic agent P = 0.008). Likewise, following adalimumab, levels decreased 6.28 1.04 m/s 5.69 1.31 0.03). In conclusion, exhibit anti‐ therapy. These findings are potential relevance due risk disease